Literature DB >> 9044874

Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols.

J J Bax1, M A Veening, F C Visser, A van Lingen, R J Heine, J H Cornel, C A Visser.   

Abstract

Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) can identify viable myocardium in patients with coronary artery disease. Recently, FDG imaging with single-photon emission tomography (SPET) and 511-keV collimators has been described. To obtain optimal image quality in all patients, cardiac FDG studies should be performed during hyperinsulinaemic glucose clamping. It has been suggested that FDG imaging after the administration of a nicotinic acid derivative may yield comparable image quality to clamping. We studied eight patients and compared the image quality of cardiac FDG SPET studies after oral glucose loading, after administration of a nicotinic acid derivative (acipimox, 250 mg orally) and during hyperinsulinaemic glucose clamping. The image quality was expressed as the myocardial to blood pool (M/B) activity ratio, which is used as a measure of the target-to-background ratio The M/B ratios were comparable after clamping and acipimox (2.8+/-0.8 vs 2.9+/-0.7), whereas the M/B ratio was lower after oral glucose loading (2.2+/-0.3, P<0.05 vs clamp and acipimox). To determine the clearance of FDG from the plasma, blood samples were drawn at fixed time intervals and the FDG activity was measured in a gamma well counter. The FDG clearance was significantly lower after oral glucose loading (T(1/2) oral load=16. 2+/-5.7 min) as compared with clamping (T(1/2) clamp=8.1+/-3.1 min) and acipimox (T(1/2) acipimox=10.7+/-4.0 min, NS vs clamp, P<0.05 vs oral load). It may be concluded that FDG SPET imaging after acipimox administration yields image quality and clearance rates comparable to those obtained during clamping. FDG SPET in combination with acipimox may useful in clinical routine for the assessment of myocardial viability.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9044874     DOI: 10.1007/bf01728306

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  20 in total

Review 1.  Fluorine-18-deoxyglucose SPECT and coincidence imaging for myocardial viability: Clinical and technologic issues.

Authors:  V Dilsizian; S L Bacharach; M M Khin; M F Smith
Journal:  J Nucl Cardiol       Date:  2001 Jan-Feb       Impact factor: 5.952

2.  Safety and feasibility of cardiac FDG SPECT following oral administration of Acipimox, a nicotinic acid derivative: Comparison of image quality with hyperinsulinemic euglycemic clamping in nondiabetic patients.

Authors:  Jeroen J Bax; Frans C Visser; Don Poldermans; Arthur Van Lingen; Abdou Elhendy; Eric Boersma; Gerrit W Sloof; Cees A Visser
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

3.  FDG PET as a predictor of response to resynchronisation therapy in patients with ischaemic cardiomyopathy.

Authors:  C M C van Campen; Frans C Visser; Arno P van der Weerdt; Paul Knaapen; Emile F I Comans; Adriaan A Lammertsma; Carel C de Cock; Cees A Visser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-09-26       Impact factor: 9.236

Review 4.  Imaging techniques in nuclear cardiology for the assessment of myocardial viability.

Authors:  Riemer H J A Slart; Jeroen J Bax; Dirk J van Veldhuisen; Ernst E van der Wall; Rudi A J O Dierckx; Pieter L Jager
Journal:  Int J Cardiovasc Imaging       Date:  2005-12-13       Impact factor: 2.357

Review 5.  Present and future of clinical cardiovascular PET imaging in Europe--a position statement by the European Council of Nuclear Cardiology (ECNC).

Authors:  D Le Guludec; R Lautamäki; J Knuuti; J J Bax; F M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-26       Impact factor: 9.236

6.  Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation.

Authors:  Michael T Osborne; Edward A Hulten; Venkatesh L Murthy; Hicham Skali; Viviany R Taqueti; Sharmila Dorbala; Marcelo F DiCarli; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2016-06-08       Impact factor: 5.952

7.  On myocardial perfusion, metabolism, and viability.

Authors:  C L Hansen; A Rastogi; R Sangrigoli
Journal:  J Nucl Cardiol       Date:  1998 Mar-Apr       Impact factor: 5.952

8.  Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression.

Authors:  James T Thackeray; Stefan Pietzsch; Britta Stapel; Melanie Ricke-Hoch; Chun-Wei Lee; Jens P Bankstahl; Michaela Scherr; Jörg Heineke; Gesine Scharf; Arash Haghikia; Frank M Bengel; Denise Hilfiker-Kleiner
Journal:  JCI Insight       Date:  2017-05-18

Review 9.  Imaging the myocardial ischemic cascade.

Authors:  Arthur E Stillman; Matthijs Oudkerk; David A Bluemke; Menko Jan de Boer; Jens Bremerich; Ernest V Garcia; Matthias Gutberlet; Pim van der Harst; W Gregory Hundley; Michael Jerosch-Herold; Dirkjan Kuijpers; Raymond Y Kwong; Eike Nagel; Stamatios Lerakis; John Oshinski; Jean-François Paul; Riemer H J A Slart; Vinod Thourani; Rozemarijn Vliegenthart; Bernd J Wintersperger
Journal:  Int J Cardiovasc Imaging       Date:  2018-03-19       Impact factor: 2.357

10.  Agreement and disagreement between contrast-enhanced magnetic resonance imaging and nuclear imaging for assessment of myocardial viability.

Authors:  Stijntje D Roes; Theodorus A M Kaandorp; Nina Ajmone Marsan; Jos J M Westenberg; Petra Dibbets-Schneider; Marcel P Stokkel; Hildo J Lamb; Ernst E van der Wall; Albert de Roos; Jeroen J Bax
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-03       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.